Protagenic Therapeutics Announces Timeline for Form 10-Q Filing and Nasdaq Compliance Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 22 2025
0mins
Source: SeekingAlpha
Quarterly Report Filing Delay: Protagenic Therapeutics announced a delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025, due to merger-related financial statement consolidation.
Anticipated Brief Delay: The company expects the delay to be short, but cannot guarantee a specific timeline for the filing.
Nasdaq Notice Received: Protagenic confirmed it received a notice from Nasdaq regarding its failure to file the Quarterly Report, although this does not affect the trading of its securities.
Current Stock Performance: Following the announcement, Protagenic's stock price increased by 1.41% after hours, reaching $4.3.
Analyst Views on PTIX
About PTIX
Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
